Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Microparticles and type 2 diabetes.

A S Leroyer1, A Tedgui, C M Boulanger

  • 1Institut National de la Santé et de la Recherche Médicale, Inserm unit 689, Cardiovascular Research Center Inserm Lariboisière, 41, bd de la Chapelle, 75475 Paris cedex 10, France.

Diabetes & Metabolism
|April 12, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting soluble CD146 with a neutralizing antibody inhibits vascularization, growth and survival of CD146-positive tumors.

Oncogene·2016
Same author

Atheroprotective immunity and cardiovascular disease: therapeutic opportunities and challenges.

Journal of internal medicine·2015
Same author

Revisited role of microparticles in arterial and venous thrombosis.

Journal of thrombosis and haemostasis : JTH·2013
Same author

Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.

Cancer metastasis reviews·2011
Same author

Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.

Clinical therapeutics·2009
Same author

[Circulating endothelial microparticles: a new marker of vascular injury].

Annales de cardiologie et d'angeiologie·2008
Same journal

Glucagon-like peptide-1 receptor agonists and risk of pancreaticobiliary cancers in patients with type 2 diabetes: a nationwide cohort study.

Diabetes & metabolism·2026
Same journal

Decreased risk of new-onset osteoporosis in patients with Type 2 diabetes on SGLT-2 inhibitors.

Diabetes & metabolism·2026
Same journal

Two faces of autoimmune hyperinsulinemia: contrasting type B insulin resistance syndrome and exogenous insulin antibody syndrome.

Diabetes & metabolism·2026
Same journal

CGM-based metrics and mortality in older adults living with type 2 diabetes on insulin therapy: a secondary analysis of the HYPOAGE study.

Diabetes & metabolism·2026
Same journal

Persistent burden and management gaps of hypoglycemia in pediatric type 1 diabetes: insights from the Epi-GLUREDIA Study.

Diabetes & metabolism·2026
Same journal

Blood oxygen saturation and its associations with autonomic and peripheral neuropathy in diabetes.

Diabetes & metabolism·2026
See all related articles

Microparticles (MPs), released from activated cells, are elevated in diabetes and cardiovascular diseases. These procoagulant vesicles may drive vascular complications through inflammation and thrombosis.

Area of Science:

  • Cardiovascular Biology
  • Endocrinology
  • Cell Biology

Background:

  • Cell activation or apoptosis releases microparticles (MPs), which are extracellular vesicles containing cell-specific oxidized phospholipids and proteins.
  • MPs are present in healthy blood but elevated in diseases like cardiovascular disease, reflecting cellular injury and vascular dysfunction.
  • Elevated MPs, especially from endothelial cells, serve as a marker for vascular dysfunction.

Purpose of the Study:

  • To investigate the role of microparticles in the pathogenesis of vascular complications in diabetes.
  • To explore how MPs contribute to inflammation, thrombosis, endothelial dysfunction, and angiogenesis in diabetic vascular disease.

Main Methods:

  • Analysis of circulating microparticle levels in healthy individuals and patients with diabetes.

Related Experiment Videos

  • Characterization of the molecular cargo (phospholipids, proteins) of microparticles.
  • In vitro studies assessing the effects of MPs on target cells, including pro-inflammatory responses, thrombosis, endothelial function, and angiogenesis.

    • Main Results:

    • Circulating microparticle levels are elevated in individuals with diabetes.
    • MPs possess procoagulant properties due to exposed phospholipids and tissue factor.
    • MPs stimulate pro-inflammatory responses, promote thrombosis, endothelial dysfunction, and angiogenesis in target cells.

    Conclusions:

    • Elevated microparticle levels are associated with diabetes and may indicate vascular dysfunction.
    • Microparticles play a significant role in the development of vascular complications in diabetes.
    • MPs represent a potential therapeutic target for managing diabetic vascular disease.